OverviewSuggest Edit

Rubius Therapeutics is developing Red-Cell Therapeutics™ (RCTs™) as a new class of medicines to address a wide array of indications, with leading applications in cancer, rare and autoimmune disease, as well as additional potential in hemophilia, infectious and metabolic diseases.

TypePublic
Founded2013
HQCambridge, MA, US
Websiterubiustx.com

Latest Updates

Employees (est.) (Apr 2019)174(+23%)
Share Price (Jan 2021)$9.2 (-5%)
Cybersecurity ratingCMore

Key People/Management at Rubius Therapeutics

Pablo J. Cagnoni

Pablo J. Cagnoni

Chief Executive Officer, Director
Christina Coughlin

Christina Coughlin

Chief Medical Officer
Andrew Oh

Andrew Oh

Chief Financial Officer
Kris Elverum

Kris Elverum

Senior Vice President, Business Development and Strategy
Spencer Fisk

Spencer Fisk

Senior Vice President & Chief Technical Operations Officer
Bryan Gillis

Bryan Gillis

Vice President, Manufacturing
Show more

Rubius Therapeutics Office Locations

Rubius Therapeutics has offices in Cambridge and Smithfield
Cambridge, MA, US (HQ)
399 Binney St #300
Smithfield, RI, US
100 Technology Way
Show all (2)

Rubius Therapeutics Financials and Metrics

Rubius Therapeutics Revenue

USD

Net income (Q2, 2020)

(37.9m)

EBIT (Q2, 2020)

(37.7m)

Market capitalization (21-Jan-2021)

747.7m

Closing stock price (21-Jan-2021)

9.2

Cash (30-Jun-2020)

129.2m

EV

737.5m
Rubius Therapeutics's current market capitalization is $747.7 m.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

General and administrative expense

2.4m22.0m39.9m57.2m

R&D expense

8.4m21.2m51.8m112.4m

Operating expense total

10.9m43.3m91.7m169.6m

EBIT

(10.9m)(43.3m)(91.7m)(169.6m)
Quarterly
USDQ1, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

General and administrative expense

1.1m5.8m16.3m13.2m13.5m13.8m15.0m12.7m11.6m

R&D expense

3.7m9.7m12.0m14.4m20.9m27.5m33.5m36.2m26.1m

Operating expense total

4.8m15.4m28.2m27.6m34.4m41.3m48.5m48.9m37.7m

EBIT

(4.8m)(15.4m)(28.2m)(27.6m)(34.4m)(41.3m)(48.5m)(48.8m)(37.7m)
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Cash

6.8m104.3m307.1m91.9m

Prepaid Expenses

53.0k700.0k

Current Assets

6.9m105.0m414.4m289.3m

PP&E

868.0k2.4m62.8m56.9m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

136.5m116.9m354.8m192.5m141.1m109.6m144.5m129.2m

Prepaid Expenses

838.0k

Current Assets

193.6m182.8m412.5m385.8m366.6m329.8m245.9m244.1m

PP&E

14.3m21.1m39.2m24.6m41.9m52.5m56.4m55.6m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(11.0m)(43.8m)(89.2m)(163.5m)

Depreciation and Amortization

118.0k447.0k1.3m3.0m

Accounts Payable

589.0k1.1m4.9m(1.0m)

Cash From Operating Activities

(9.5m)(21.9m)(58.3m)(110.4m)
Quarterly
USDQ1, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(4.9m)(15.3m)(44.4m)(62.0m)(32.6m)(72.0m)(119.0m)

Depreciation and Amortization

48.0k227.0k502.0k879.0k661.0k1.4m2.3m1.8m3.6m

Accounts Payable

937.0k452.0k3.0m2.4m(966.0k)(4.7m)3.2m905.0k3.1m

Cash From Operating Activities

(3.1m)(10.9m)(20.8m)(38.6m)(22.9m)(52.7m)(81.5m)(40.0m)(68.6m)
USDFY, 2016

Debt/Equity

6.3 x

Debt/Assets

1.5 x

Financial Leverage

4.1 x
Show all financial metrics

Rubius Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

C

78/100

SecurityScorecard logo

Rubius Therapeutics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

50-59

out of 100

CSRHub logo

Rubius Therapeutics Online and Social Media Presence

Embed Graph

Rubius Therapeutics News and Updates

Rubius Therapeutics Provides Operational Update and Outlines 2021 Objectives at the 39th Annual J.P. Morgan Healthcare Conference

Initial Clinical Data Show RTX-240 Stimulates Innate and Adaptive Immunity (NK Cells and T Cells) Supporting Proof of Mechanism – Additional Results to be Presented in Early 2021

Rubius Therapeutics Reports Third Quarter 2020 Financial Results and Strong Execution Across the Pipeline

Completed Dosing of Fourth Cohort in RTX-240 Phase 1/2 Solid Tumor Clinical Trial

Rubius Therapeutics Presents Preclinical Data for RTX-321, a Red Cell Therapeutic™ Oncology Product Candidate for HPV-Positive Cancers, Demonstrating its Dual Mechanism of Action

RTX-321 Induces Antigen-Specific Stimulation Combined with Broad Stimulation of Innate and Adaptive Immune Responses RTX-321 Induces Antigen-Specific Stimulation Combined with Broad Stimulation of Innate and Adaptive Immune Responses

Rubius Therapeutics Announces Preclinical Data Supporting its Lead Clinical Oncology Program, RTX-240, to be Presented at the Society for Immunotherapy of Cancer’s Annual Meeting

CAMBRIDGE, Mass., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced that the company will present preclinical d…

Rubius Therapeutics Appoints Jose Carmona as Chief Financial Officer

CAMBRIDGE, Mass., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced the appointment of Jose “Pepe” Carmona as …

Rubius Therapeutics Reports Second Quarter 2020 Financial Results and Positive Progress Across Pipeline

Strong Momentum in Dosing Patients and Manufacturing Clinical Supply for RTX-240 Phase 1/2 Solid Tumor Clinical Trial
Show more

Rubius Therapeutics Blogs

Rubius Therapeutics to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference

Rubius Therapeutics to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference Content Import Mon, 01/04/2021 - 16:01 Rubius Therapeutics to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference January 4, 2021 This release is a bac…

Rubius Therapeutics to Participate in Evercore ISI 3rd Annual HealthCONx Conference

CAMBRIDGE, Mass. , Nov. 30, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announced that Pablo J.

Rubius Therapeutics Named to the List of Top Places to Work in Massachusetts by the Boston Globe and Top 5 Best Places to Work in Rhode Island by Providence Business News

Rubius Therapeutics Named to the List of Top Places to Work in Massachusetts by the Boston Globe and Top 5 Best Places to Work in Rhode Island by Providence Business News Brian.Hoenig@n… Fri, 11/20/2020 - 09:27 Rubius Therapeutics Named to the List of Top Places to Work in Massachusetts by…

Rubius Therapeutics to Participate in Jefferies Virtual London Healthcare Conference

Rubius Therapeutics to Participate in Jefferies Virtual London Healthcare Conference Content Import Tue, 11/10/2020 - 16:02 Rubius Therapeutics to Participate in Jefferies Virtual London Healthcare Conference November 10, 2020 This release is a backfill from a…

Rubius Therapeutics Presents Preclinical Data for Lead Red Cell Therapeutic™ Clinical Oncology Program, RTX-240, at the Society for Immunotherapy of Cancer’s Annual Meeting

Rubius Therapeutics Presents Preclinical Data for Lead Red Cell Therapeutic™ Clinical Oncology Program, RTX-240, at the Society for Immunotherapy of Cancer’s Annual Meeting Content Import Mon, 11/09/2020 - 08:02 Rubius Therapeutics Presents Preclinical Data for Lead Red Cell Therapeutic™ C…

RTX-240, an Allogeneic Engineered Red Blood Cell Expressing 4-1BBL and IL-15TP, Promotes NK Cell Functionality In Vitro and In Vivo

Anne-Sophie Dugast, Shannon L. McArdel, Enping Hong, Arjun Bollampalli, Maegan E. Hoover, Sneha Pawar, Viral Amin, Kangjian Qiao, Christopher Ta, Laurence A. Turka, Thomas J. Wickham, Sivan Elloul SITC 2020 RTX-240 Audio Recording Your browser does not support the audio element. The post RTX-240, an…
Show more

Rubius Therapeutics Frequently Asked Questions

  • When was Rubius Therapeutics founded?

    Rubius Therapeutics was founded in 2013.

  • Who are Rubius Therapeutics key executives?

    Rubius Therapeutics's key executives are Pablo J. Cagnoni, Christina Coughlin and Andrew Oh.

  • How many employees does Rubius Therapeutics have?

    Rubius Therapeutics has 174 employees.

  • Who are Rubius Therapeutics competitors?

    Competitors of Rubius Therapeutics include ImCheck Therapeutics, Confo Therapeutics and Opthea.

  • Where is Rubius Therapeutics headquarters?

    Rubius Therapeutics headquarters is located at 399 Binney St #300, Cambridge.

  • Where are Rubius Therapeutics offices?

    Rubius Therapeutics has offices in Cambridge and Smithfield.

  • How many offices does Rubius Therapeutics have?

    Rubius Therapeutics has 2 offices.